EUTEMA RESEARCH SERVICES GMBH

Their core work

EUTEMA Research Services GmbH is a Vienna-based private research services company that embeds as a specialist partner in European research consortia across different scientific domains. The name "Research Services" is telling: rather than owning a single technology or laboratory discipline, they appear to offer transferable methodological, regulatory, or project support capabilities that can serve projects ranging from border surveillance technology to clinical transplantation trials. Their two H2020 projects sit in entirely different pillars (Security and Health), which strongly suggests their value lies in process expertise — clinical trial management, regulatory affairs, dissemination, or research coordination — rather than deep domain science. This makes them an unusual but potentially useful consortium partner for projects that need structured research support without adding another technology-specialist lab.

What they specialise in

How they've shifted over time

EUTEMA's early H2020 engagement (2018) was in security technology — specifically detection systems for border surveillance in challenging physical environments, a hardware and sensing-oriented field. By 2021 their work had pivoted entirely to clinical medicine, supporting a randomised trial on kidney transplantation and immunosuppression management guided by torque teno virus load as a biomarker. These two domains share almost no scientific content, which points to an organisation whose expertise is in the research process itself — managing complex multi-partner studies — rather than in any specific technology. The trajectory suggests increasing focus on health and clinical research services, where regulatory complexity and trial management create sustained demand for specialist support providers.

EUTEMA appears to be moving toward health and clinical research services, with their most recent and better-funded project centred on a multi-year Phase II transplantation trial — a domain that will sustain activity well into 2026 and likely beyond.

How they like to work

EUTEMA has never led an H2020 project, participating exclusively as a consortium partner in both projects to date. Despite only two projects, they have accumulated 42 unique consortium partners across 16 countries, which implies involvement in large, multi-institutional RIA consortia where many organisations collaborate simultaneously rather than repeat bilateral partnerships. This pattern suggests they are comfortable operating within large, distributed teams and are likely sought for a specific service or compliance role rather than for scientific leadership.

EUTEMA has reached 42 distinct partner organisations across 16 countries through just two projects, reflecting the scale of the RIA consortia they joined rather than a personally cultivated network. Their geographic spread is broadly European with no discernible regional concentration evident from the available data.

What sets them apart

EUTEMA's defining characteristic is sector agnosticism: they have contributed meaningfully to projects in both security technology and clinical medicine, which is rare for an SME and suggests a service offering that is domain-independent — likely clinical research management, regulatory support, or EU project administration. For consortium builders who need a reliable, experienced research services partner without adding scientific overlap, EUTEMA fills a distinct gap. Their Austrian base in Vienna also positions them well for Central and Eastern European consortium dynamics.

Highlights from their portfolio

• TTV GUIDE TX
  Their largest and most recent project (€473,250, running to 2026), this Phase II randomised clinical trial on using torque teno virus load to personalise immunosuppression after kidney transplantation represents a sophisticated clinical research environment and is still active.
• FOLDOUT
  Demonstrates rare cross-domain range — participation in a security-pillar project on through-foliage detection for EU border surveillance shows EUTEMA's ability to contribute outside the health sector entirely.